Podcasts about associate chairman

Dr. David Williams, Chief of the Division of Hematology & Oncology at Boston Children's Hospital, Associate Chairman of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute, and Leland Fikes Professor of Pediatrics at Harvard Medical School March 15, 2024 In this episode, we discuss advances in gene therapy and its use in treating pediatric patients. Using modified viruses as delivery vehicles, researchers and clinicians can target therapies to specific types of cells, providing patients with long-lasting—and potentially life-long—treatments for a variety of severe genetic conditions. Future advances hope to make these therapies less expensive, less invasive, and more accessible for patients around the world and to expand their use for more common conditions.

Rich Greiner, Emergency Physician and Associate Chairman of Emergency Medicine at Yale New Haven Health's Bridgeport Hospital provides an introduction to his background while sharing his perspective on challenges faced in today's healthcare landscape and managing overstressed and understaffed workforces in Emergency Rooms. As an experienced leader, Rich offers practical advice for emerging physician leaders, outlining how they can make a meaningful impact.

Today we have Dr. Brian Cole, an orthopedic surgeon who specializes in cartilage restoration, orthobiologics, and advanced surgical techniques for the treatment of knee, elbow, and shoulder injuries. He is the team physician for the NBA's Chicago Bulls and the co-team physician for the Chicago White Sox. He also is the host of the Sports Medicine Weekly Podcast. Brian practices orthopedic sports medicine at Midwest Orthopaedics. He also is a professor of Orthopaedics, Anatomy and Cell Biology at Rush University Medical Center in Chicago. He is Managing Partner of Midwest Orthopaedics and is the department's Associate Chairman and the Section Head of the Cartilage Research and Restoration Center. In addition to this work, he also serves as the Chairman of Surgery at Rush Oak Park Hospital. In today's interview, we talk to Brian about his cutting-edge research into ways to treat knee, shoulder, and elbow injuries.  Brian shares his novel approach to dealing with ACL tears, one of the most common sports injuries, and his investigations of methods to enhance the healing and recovery time following ACL reconstructions. He also talks about new advances in minimally invasive surgical techniques for many common injuries.  We have a particularly interesting conversation with Brian about exciting developments in the use of stem-cell treatments as well as the use of bone marrow aspirate to treat injuries. Show notes: [00:03:53] Marcas opens the interview mentioning that Brian was in the eighth grade when he fell in love with a popular sit-com from the 1970s,  “The Bob Newhart Show.” Marcas asks Brain what he loved about the show and what impact it had on him. [00:05:07] Brian enrolled in the University of Illinois after graduating from high school. Marcas asks Brian if knew he wanted to major in biology and psychology when he arrived on campus. [00:05:58] Ken mentions that after Brian's undergrad, he travelled upstate to the University of Chicago, where he earned an MD and an MBA. Ken asks what led Brian to pursue both an MD and MBA. [00:09:52] Ken explains that after the University of Chicago, Brian moved to New York City for an orthopaedic research fellowship in metabolic bone disease at the Hospital for Special Surgery. Brian also decided to do his residency there as well. Ken asks how that came about. [00:11:31] Marcas mentions that after Brian finished his fellowship and residency, he went to the University of Pittsburgh for a sports medicine fellowship. Marcas asks what led Brian there and what drove his interest in sports medicine. [00:13:10] Marcas asks Brian about a fortuitous phone call he received when he was a fourth-year resident. [00:14:34] Ken explains that Midwest Orthopaedics is one of the nation's most respected private orthopaedic practices.  Ken notes that through a partnership with Rush University Medical Center, Midwest has developed a national reputation as a leader in sports medicine; hip, knee, spine, and cartilage restoration; as well as shoulder care and pain management. Rush also is an academic medical center that includes a 671-bed hospital and is a center for basic and clinical research. Ken asks Brian to describe the scope of the work that goes on at Midwest and Rush. [00:17:20] Marcas comments that Brian is also the head team physician for the Chicago Bulls and the co-team physician for the Chicago White Sox, and asks Brian to describe some of the work that he does in that capacity. [00:20:09] Marcas explains that Brian treats a wide range of patients with injuries and pain, from athletes to non-athletes, and from children to senior citizens, and that he has performed more than 20,000 surgeries over the course of his career. Marcas asks Brian to give a sense of the patients he sees and what his average day at the office is like. [00:24:00] Ken points out that Brian is known for focusing on treating the patient and not the x-ray or MRI.

In this episode Maxwell Cooper, MD interviews Brian Cole, MD, MBA, Managing Partner of Midwest Orthopaedics at Rush, Associate Chairman of Orthopaedic Surgery at Rush University Medical Center, and Head Team Physician for the Chicago Bulls of the NBA, Chicago White Sox of the MLB, and several other professional and collegiate teams. Dr. Cole gives an overview of his practice as a orthopedic surgeon specializing in sports medicine and caring for professional athletes. He also gives an overview of the business operations of Midwest Orthopaedics at Rush, a physician run, independent fully comprehensive orthopaedic practice that also serves as the academic orthopaedics department for Rush University. Dr. Cole discusses how Midwest Orthopaedics at Rush is optimized with many sources of revenue beyond a high-volume surgical practice and how the practice is able to conduct high-level clinical and basic science research. Lastly, Dr. Cole discusses his podcast, Sports Medicine Weekly where he interviews a variety of guests to provide education to the community covering sports medicine, health and wellness, and many more topics.  *Views expressed in this podcast are those of the individuals, not their respective institutions   Thank you to our sponsor Doc2Doc Lending, the Personal Lending platform designed for Doctors, by Doctors. Check out https://doc2doclending.com/davinci to learn more today.   Brian Cole, MD, MBA Website: https://www.briancolemd.com/ Instagram: https://www.instagram.com/brianjcolemd/ Twitter: https://twitter.com/BrianColeMD Sports Medicine Weekly Podcast: https://sportsmedicineweekly.com/   The DaVinci Hour Podcast Website: https://www.dviacademy.com/the-davinci-hour LinkedIn: https://www.linkedin.com/company/the-davinci-hour/ DaVinci Academy YouTube: https://www.youtube.com/c/DaVinciAcademyMed/ Website: https://www.dviacademy.com/

This episode is brought to you by Heron Therapeutics. Please see full Prescribing Information, including Boxed Warning or visit www.ZYNRELEF.com. This episode is also brought to you by TrackableMed, grow your new patients. We have the one and only Dr. Brian Cole for this episode. Dr. Brian Cole is an orthopedic sports medicine surgeon at Midwest Orthopaedics at Rush and a Professor of Orthopaedics, Anatomy and Cell Biology at Rush University Medical Center. Dr. Cole is Managing Partner of Midwest Orthopaedics and is the Department's Associate Chairman and the Section Head of the Cartilage Research and Restoration Center. He's one of the most prolific and most influential sports medicine surgeons in the world. Dr. Cole is the head team physician for the Chicago Bulls and co-team physician for the Chicago White Sox. He's a member of every society for sports medicine orthopedics with a vast history of experience with a passion for education. This is one you're going to enjoy! Topics include:-He discusses what made him decide to become a physician and the influence going into orthopedics, including residency at the Hospital for Special Surgery at Cornell Medical Center, and a Sports Medicine fellowship at the University of Pittsburgh. Dr. Cole talks about how he made his way back to Chicago after fellowship at Midwest Orthopaedics at Rush and helping to build the cartilage restoration program. -He talks about the "private-demic" model of Rush, running it as a private practice with the benefits of being in the academic world. It's a private independent practice that fosters entrepreneurialism. -Dr. Cole has a passion for fellowships and can hear his devotion for the importance of mentorships. He discusses how it's essential to positively influence the next generation through fellowships. -We also hear about what is his work//life balance like with all of his responsibilities. Find out more about Dr. Brian Cole here. Also, find out more about Zynrelef here: ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is the first and only extended-release dual-acting local anesthetic™ (DALA™) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery. -ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF's indication. -Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use • ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events ZYNRELEF is contraindicated for: • Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs,

Can you fully understand your patient's perspective without first understanding their religious or spiritual inclinations? When it comes to treating spiritual patients, Dr. Jim Lomax, M.D., contends that knowing their steadfast beliefs is a crucial factor in understanding their reactions and needs in mental health care. He urges clinicians to leave behind the notion that understanding a patient's spirituality is antithetical to therapy or “anti-science.” Dr. Jim Lomax is the Karl Menninger Chair for Psychiatric Education, former Brown Foundation Chair for Psychoanalysis, and Associate Chairman and Director of Educational Programs in the Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine.Join hosts Dr. Bob Boland and Dr. Kerry Horrell on this episode of Mind Dive podcast as Dr. Lomax draws on his expertise and experience to express to clinicians the importance of understanding a patient in the midst of spiritual struggle. He explores the notion that positive religious coping can be a beneficial tool in some mental health journeys. “To simply be curious and to wonder with patients is a real value,” said Dr. Lomax, “This is one of the best ways to produce a sense of healing as restoration to community for your patients.” Follow The Menninger Clinic on Twitter, Facebook, Instagram and LinkedIn to never miss an episode. Visit www.menningerclinic.org to learn more about The Menninger Clinic's research and leadership roles in mental health. Listen to Episode 6: Building Trust in Therapeutic Relationships with Dr. Jon Allen

This week Jacob visits with Dr. Patrick Friman. ​​​​Dr. Patrick C. ​​F​riman received his Ph.D. from the University of Kansas. He is the current Vice ​President of ​Outpatient Behavioral Health Services and a Clinical Professor in the Department of Pediatrics at the University of Nebraska School of Medicine. He was formerly on the faculties of Johns Hopkins, University of Pennsylvania, and Creighton Schools of Medicine. He was also formerly the Director of the Clinical Psychology Program at University of Nevada as well as the Associate Chairman of the Department of Psychology. Dr. Friman is the former Editor of the Journal of Applied Behavior Analysis and former President of the Association for Behavior Analysis International. He is also on the editorial boards of eight peer reviewed journals. He has published more than 180 scientific articles and chapters and three books. The primary focus of his scientific and clinical work in is in the area of Behavioral Pediatrics and Behavioral Medicine. Dr. Friman's work in behavioral pediatrics has concentrated on the gap between primary medical care for ​children on one side, and referral-based clinical child psychological and psychiatric care, on the other. He also specializes in consultation regarding workplace issues such as motivation, dealing with difficult people, change, and pathways to success. As an example of the impact of his work, following a publication on child sleep problems, the American Medical Association ​invited him to headline a press conference in New York City where he was presented to the press by the Surgeon General of the United States. Real Conversations with Jacob Young is brought to you by Boys Town.  FOLLOW JACOB: Instagram  Facebook Twitter  

Orthobiologics such as platelet-rich-plasma, and stem cells have gained popularity as treatments for knee osteoarthritis over recent years. Orthobiologics are cells, blood components or growth factors which claim to promote healing and decrease inflammation. Platelet rich plasma and stem cell injections are an expensive treatment and there is a paucity of rigorous evidence to support the use of them in people with OA. On this episode of Joint Action, we are joined by Dr. Brian Cole to unpack the controversial topic of osteoarthritis orthobiologics.Dr. Brian Cole is an orthopedic sports medicine surgeon at Midwest Orthopaedics at Rush and a Professor of Orthopaedics, Anatomy and Cell Biology at Rush University Medical Center. Dr. Cole is Managing Partner of Midwest Orthopaedics and is the Department's Associate Chairman and the Section Head of the Cartilage Research and Restoration Center. He is the Chairman of Surgery at Rush Oak Park Hospital and leads the Rush Orthopedic Master's Program. Dr. Cole is the 2020 President of the Arthroscopy Association of North America.

Orthobiologics such as platelet-rich-plasma, and stem cells have gained popularity as treatments for knee osteoarthritis over recent years. Orthobiologics are cells, blood components or growth factors which claim to promote healing and decrease inflammation. Platelet rich plasma and stem cell injections are an expensive treatment and there is a paucity of rigorous evidence to support the use of them in people with OA. On this episode of Joint Action, we are joined by Dr Brian Cole to unpack the controversial topic of osteoarthritis orthobiologics. Dr. Brian Cole is an orthopedic sports medicine surgeon at Midwest Orthopaedics at Rush and a Professor of Orthopaedics, Anatomy and Cell Biology at Rush University Medical Center. Dr. Cole is Managing Partner of Midwest Orthopaedics and is the Department's Associate Chairman and the Section Head of the Cartilage Research and Restoration Center. He is the Chairman of Surgery at Rush Oak Park Hospital and leads the Rush Orthopedic Master's Program. Dr. Cole is the 2020 President of the Arthroscopy Association of North America. Dr. Cole's research interests include Cartilage Restoration, therapeutic biologics and regenerative medicine, and minimally invasive surgical techniques for the treatment of the knee, elbow, and shoulder. He has published more than 1,000 articles and 8 textbooks on orthopedic surgery and sports medicine, has lectured nationally and internationally on more than 2,000 occasions and has appeared as an expert on several TV documentaries.His professional career outside of academia includes serving as team physician for the Chicago Bulls, co-team physician for the Chicago White Sox, and a team physician for the Chicago Fire, Chicago Dogs, and DePaul University. He has served as co-host for 10 years on the radio talk-show Sports Medicine Weekly originally on ESPN and currently on 670TheScore – Chicago Sports Radio.RESOURCESSCulPTOR study investigating stem cell injections in persons with knee osteoarthritis in Sydney, Australia and Hobart, Tasmania. For more information and to check your eligibility, check out the website. CONNECT WITH BRIANTwitter: @BrianColeMDSports Medicine Weekly PodcastWebsite: https://www.briancolemd.com/CONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! See acast.com/privacy for privacy and opt-out information.

Covering:*Dr Cole’s background*Lessons learned from sports growing up*Qualities of a good mentor*Traits of a leader and steps you can take to become a better leaderDr. Brian Cole graduated from the University of Chicago Pritzker School of Medicine and completed his residency in Orthopedics at Hospital For Special Surgery/Cornell Med Center. Moreover, he completed his fellowship in Sports Medicine at University of Pittsburgh. Dr. Brian Cole is a well-known orthopaedic surgeon who specializes in sports medicine for knee, shoulder, and elbow . Dr. Cole is also the current president of the Arthroscopy Association of North America and holds leadership positions in multiple societies in the field of sports medicine. He is the chairman of surgery at Rush Oak Park Hospital and is the head team physician for the Chicago Bulls NBA team, co- team physician for the Chicago White Sox MLB team and DePaul University in Chicago. He has published over 1000 articles and has given numerous national and international talks on a variety of subjects.In 2009, he was recognized by his colleagues as one of the top 20 sports medicine, knee, and shoulder experts over the past five years and was selected as NBA Team Physician of the Year. Since 2004, he has been named one of the “Best Doctors in America” and a “Top Doctor” in Chicagoland since 2003.Also, Dr. Brian Cole is a professor of orthopaedics, anatomy, and cell biology at Rush University Medical Center and an orthopedic sports medicine surgeon at Midwest Orthopaedics at Rush. Moreover, he is the Managing Partner of Midwest Orthopaedics, as well as the Department’s Associate Chairman and the Cartilage Research and Restoration Center’s Section Head. He is also the host of the sports medicine weekly podcast!Learn more about Dr. Cole at: https://www.briancolemd.com/

Dr. Brian Cole graduated in the University of Chicago Pritzker School of Medicine and completed his residency in Orthopedics at Hospital For Special Surgery/Cornell Med Center. Moreover, he completed his fellowship in Sports Medicine at University of Pittsburgh. Dr. Brian Cole is a well-known orthopaedic surgeon who specializes in sports medicine for knee, shoulder, and elbow .  Dr. Cole is also the current president of the Arthroscopy Association of North America and holds leadership positions in multiple societies in the field of sports medicine. He is the chairman of surgery at Rush Oak Park Hospita and is the head team physician for the CHicago Bulls NBA team, co- team physician for the CHicago White Sox MLB team and DePaul University in Chicago.He has published over 1000 articles and has given numerous national and internal talks on a variety of subjects. In 2009, he was recognized by his colleagues as one of the top 20 sports medicine, knee, and shoulder experts over the past five years and was selected as NBA Team Physician of the Year. Since 2004, he has been named one of the "Best Doctors in America" and a "Top Doctor" in Chicagoland since 2003. Also, Dr. Brian Cole is a professor of orthopaedics, anatomy, and cell biology at Rush University Medical Center and an orthopedic sports medicine surgeon at Midwest Orthopaedics at Rush. Moreover, he is the Managing Partner of Midwest Orthopaedics, as well as the Department's Associate Chairman and the Cartilage Research and Restoration Center's Section Head. Learn more about Dr. Cole at: https://www.briancolemd.com/ Goal of episode: To develop a baseline knowledge on Leadership & Life Lessons. We cover: Dr Cole’s background Lessons learned from sports growing up Qualities of a good mentor Traits of a leader and steps you can take to become a better leader    

In this episode Arash and Dr. Cole discuss shoulder arthritis in this episode. Specifically what interventions to provide with the young patient in the clinic presenting with shoulder arthritis. We discuss what shoulder arthritis is and how someone with arthritis may present.  We then discuss interventions including supplementation, physical therapy, injections, and common procedures that Dr. Cole performs with this population. Dr. Brian Cole is an orthopedic sports medicine surgeon at Midwest Orthopaedics at Rush and a Professor of Orthopaedics, Anatomy and Cell Biology at Rush University Medical Center. Dr. Cole is Managing Partner of Midwest Orthopaedics and is the Department’s Associate Chairman and the Section Head of the Cartilage Research and Restoration Center. He is the Chairman of Surgery at Rush Oak Park Hospital and leads the Rush Orthopedic Master’s Program. Dr. Cole also holds several leadership positions in national and international orthopedic societies.  Enjoy!    -The Prehab Guys    Guest: Dr. Brian Cole  Instagram: @ShoulderKneeDoc  Learn more about the Shoulder [P]Rehab Program HERE. Learn more about the Knee [P]Rehab Program HERE. Visit our website: www.theprehabguys.com  Follow us on: Instagram | Facebook | Youtube | Twitter    Connect with The Prehab Guys  info@theprehabguys.com    Leave feedback, let us know what to talk about next. Did you enjoy this? Don't forget to rate, reviewm and subscribe. 

Dr. Sparano is Professor of Medicine & Obstetrics, Gynecology, and Women's Health at the Albert Einstein College of Medicine, Associate Chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, and Associate Director for Clinical Research at the Albert Einstein Cancer Center. He also serves as Vice Chair of the ECOG-ACRIN Research Group and Vice Chair of the AIDS Malignancy Consortium. He is former director of the Hematology-Oncology Fellowship Program at Einstein/Montefiore,  co-directs the ECOG-ACRIN Young Investigator Program, and is a faculty member of the Calabresi K12 Oncology Training Program.  He is co-principal investigator of the Montefiore-Einstein Minority/Underserved National Community Oncology Research Program (NCORP) grant (in conjunction with Dr. Bruce Rapkin), which funds multicenter, NCI-sponsored clinical trials in cancer therapeutics, cancer prevention/control, and cancer care delivery research.  He is also the recipient of funding from the Breast Cancer Research Foundation that is supporting creation of a biospecimen bank designed to identify determinants of late relapse. Dr. Sparano is a practicing clinician who specializes in medical oncology and clinical and translational cancer research. His research has focused on developmental therapeutic approaches for breast cancer, lymphoma, and HIV-associated cancers, and therapeutic application of molecular profiling in cancer. TRANSCRIPT Welcome to the ASCO University Weekly Podcast. My name is Joseph Sparano, and I am Associate Director for Clinical Research at the Albert Einstein Cancer Center, and chief of the section of breast medical oncology at Montefiore Medical Center in New York. Today, we contrast two cases on adjuvant treatment of breast cancer. The standard treatment for hormone receptor positive, HER2 negative, early stage breast cancer is surgery, followed by endocrine therapy. Since the early 2000s, adjuvant chemotherapy has also been recommended to the majority of these women, but the added benefit from chemotherapy is modest for most. Many different gene expression assays have been developed to determine prognosis and identify which woman may be more likely to benefit from chemotherapy. One commercial test that is recommended in clinical practice guidelines is a 21 gene recurrence score assay. Based on the recently completed TAILORx study, it was known that woman with low recurrence scores on the 21 gene expression assay do well with adjuvant endocrine therapy alone. Whereas woman with high recurrence scores benefit from adjuvant endocrine therapy and chemotherapy. The TAILORx study clarified the best treatment option for women with an intermediate recurrence score, which was defined as a recurrence score of 11 to 25 in the trial. This is particularly important because the majority of patients fall in this intermediate risk category, up to 70%, in fact. Before we discuss the new evidence reported from this study, let's take a look at two intermediate risk cases. These two cases are very similar, yet the recommended treatments may be very different. Can you identify the key differences between these two cases? We begin with the first case. Case 1 is a 55-year-old postmenopausal woman with a node negative, ER positive, PR positive, HER2 negative breast cancer. The size of the tumor is 1.6 sonometers. The 21-gene recurrence score is 24, which is in the upper range of the intermediate risk category. Which option would you recommend as the best systemic treatment. The choices in this case include endocrine therapy alone or chemotherapy followed by endocrine therapy. The correct answer to this question is, A, endocrine therapy alone. We will discuss the rationale for this recommendation shortly, but first let's move on to the second case. The second case is a 44-year-old premenopausal woman with node negative, ER positive, PR positive, HER2 negative breast cancer. Like case 1, the size of the tumor is 1.6 centimeters and the 21-gene recurrence score is 24. Which option would be the best adjuvant treatment in this case? The choices here include endocrine therapy alone or chemotherapy, followed by endocrine therapy. The correct answer in this case is chemotherapy, followed by endocrine therapy. Both of these cases had nearly identical clinical presentations. That is, they presented with ER, PR positive, HER2 negative breast cancer, associated with negative axillary nodes, a primary tumor size of 1.6 sonometers, and a 21-gene recurrence score of 24. However, the key difference was the age at presentation, with one patient being in her mid 50's and postmenopausal, and the other patient being in her mid 40's and premenopausal. The TAILORx trial found that endocrine therapy was not inferior to chemotherapy plus endocrine therapy in the overall population with a mid-range 21-gene recurrence score of 11 to 25. However, there was an interaction between age, chemotherapy treatment, and recurrence score. About 1/3 of women who participated in the trial were 50 or younger. These women seem to have some chemotherapy benefit if the recurrence score was between 16 and 25. For those who had a recurrence score of 21 to 25, the absolute reduction in the risk of distant recurrence was approximately 7% at 9 years. For a woman who had a recurrence score of 16 to 20, the absolute reduction in distant recurrence by the addition of chemotherapy was about 2%. It remains unclear as to whether the benefit from chemotherapy in younger woman was due to a true cytotoxic effect associated with chemotherapy in eradicating micrometastatic disease, or a castration effect in inducing early menopause. Nevertheless, the findings from the TAILORx trial provide the highest level of evidence supporting the greatest level of precision in using the 21-gene assay to guide the use of adjuvant chemotherapy in early stage breast cancer. Thank you for listening to this week's episode of the ASCO University Weekly Podcast. For more information on the adjuvant treatment of breast cancer, including additional patient cases and opportunities for self-evaluation, visit the comprehensive e-learning center at university.asco.org. Thank you for your attention. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In Episode 3 of The Sports Medicine Podcast, Dr. Dold sits down with Chicago-based orthopedic surgeon and cartilage expert, Dr. Brian Cole of Midwest Orthopaedics at Rush University. Dr. Cole is a Professor in the Department of Orthopedics with a conjoint appointment in the Department of Anatomy and Cell Biology at Rush University Medical Center in Chicago, Illinois. In 2015, he was appointed as an Associate-Chairman of the Department of Orthopedics at Rush. He is the Section Head of the Cartilage Research and Restoration Center at Rush specializing in the treatment of arthritis in young active patients with a focus on regenerative medicine and biologic alternatives to surgery. He also serves as the head of the Orthopedic Master's Training Program and trains residents and fellows in sports medicine and research. He lectures nationally and internationally and holds several leadership positions in prominent sports medicine societies. Through his basic science and clinical research, he has developed several innovative techniques for the treatment of shoulder, elbow and knee conditions. He has published more than 1,000 articles and 10 widely read textbooks in orthopedics and regenerative medicine. Dr. Cole is the head team physician for the Chicago Bulls NBA team, co-team physician for the Chicago White Sox MLB team and DePaul University in Chicago. For more information on Dr. Cole, please visit: https://www.briancolemd.com https://www.rushortho.com/doctors/brian-j-cole This episode is sponsored by: TerumoBCT (previously Harvest Technologies) The Sports Medicine Podcast Instagram: https://www.instagram.com/thesportsmedicinepodcast/ Feedback: thesportsmedicinepodcast@gmail.com Web: www.thesportsmedicinepodcast.com Host: Dr. Andrew Dold, MD FACS FRCSC DoldMD.com @dr.dold.md https://www.instagram.com/dr.dold.md/

Hypoglycemia..."The Boogeyman under the bed"... Everything you ever wanted to know about Hypoglycemia, but were afraid to ask… Today on DiabetesPowerShow, we ask one of the finest Endocrinologists in the country, Dr. C. R. Kannan, the tough questions about this dreadful condition. Somehow, the DPS team manages to produce a fun, and funny show involving a very serious topic, Hypoglycemia, while learning more than we ever knew about it.   Joining us today in studio, C. R. Kannan, M. D. Dr. Kannan is presently Director of Endocrinology and Metabolism at Red Rock Medical Center in Las Vegas.  He served as Professor of Internal Medicine at the University of Nevada School of Medicine in Las Vegas from 2009 to 2013, with teaching and patient responsibilities. He was also Consultant in Endocrinology at Southwest Medical Associates in Las Vegas, from 2003 to 2010. He moved to Nevada in 2003, following many years of academic and clinical practice in Chicago. He is the former Chairman of Endocrinology at Cook County Hospital in Chicago, and Associate Chairman of Endocrinology at Rush Presbyterian St. Luke’s Medical Center. He was responsible for the combined Endocrinology Fellowship Program of Rush Presbyterian and Cook County Hospitals.  He is a tenured Professor of Medicine at Rush University, Chicago. During his tenure at Cook County and Rush Presbyterian, he won the Teacher of the Year Award ten (10) times. He has single-authored four (4) medical textbooks, and has served as an editor of the Year Book of Endocrinology for 15 years.  He has also co-authored several original articles in peer-reviewed journals.   DiabetesPowerShow Co-Host, Chris Daniel, who has Type One Diabetes, often experiences Hypoglycemia Unawareness. So when he repels off of a 300 foot cliff, his glucose numbers have to be in check. Last weekend, Chris tested his adventuresome skills at beautiful Lake Powell, where he pushed himself to the limit. Check out pics at DiabetesPowerShow.com  

My guest for episode #220 is somebody I've wanted to interview for a long time, Dr. Robert Wachter, one of the leading voices in the modern patient safety movement. He's most recently author of a brand-new book The Digital Doctor: Hope, Hype, and Harm at the Dawn of Medicine's Computer Age. His book was excerpted in this New York Times Op-Ed piece, "Why Health Care Tech Is Still So Bad." In this episode, we cover topics including: How Bob got into the patient safety field Of all of the estimates of patient harm and death caused by medical errors, which does he find most valid? His perspectives on the interface between Lean principles and practices and the modern patient safety movement What were some of the pros and cons of the $30 billion in federal government incentives for EMR/EHR adoption? Is it fair to say that EHR systems solve some patient safety problems while solving others? Some of the new waste introduced by new "meaningful use" regulations The story of a preventable medication error that harmed a child - a combination of technology problems, human factors, and bad process Finding the balance between "system problems" and personal accountability (see this article) Disclosure: I received an advance copy of The Digital Doctor from the publisher. I highly recommend the book for its balanced presentation of the promise, successes, and challenges of healthcare IT. The book discusses why electronic medical records haven't been adopted more quickly, why government incentives were introduced, and EMR/EHR systems are not the panacea that some had promised. Previously, Dr. Wachter has written books on patient safety (that I've read and recommend) including Understanding Patient Safety and Internal Bleeding. He received one of the 2004 John M. Eisenberg Awards, the nation's top honor in patient safety and quality. He has been selected as one of the 50 most influential physician-executives in the U.S. by Modern Healthcare magazine for the past seven years, the only academic physician to achieve this distinction. I was honored when Dr. Wachter recently interviewed me about Lean and patient safety for his AHRQ "Web M&M" series. Dr. Wachter is Professor and Associate Chairman of the Department of Medicine at the University of California, San Francisco, where he holds the Lynne and Marc Benioff Endowed Chair in Hospital Medicine. He is also Chief of the Division of Hospital Medicine, and Chief of the Medical Service at UCSF Medical Center. He has published 250 articles and 6 books in the fields of quality, safety, and health policy. He coined the term "hospitalist" in a 1996 New England Journal of Medicine article and is past-president of the Society of Hospital Medicine. He is generally considered the academic leader of the hospitalist movement, the fastest growing specialty in the history of modern medicine. For a link to this episode, refer people to www.leanblog.org/220. Podcasts are sponsored by KaiNexus and their continuous improvement software platform -- www.KaiNexus.com For earlier episodes of the Lean Blog Podcast, visit the main Podcast page at www.leanpodcast.org, which includes information on how to subscribe via RSS or via Apple iTunes.Joining me for episode #219 is Tristan Kromer, a professional "Lean Startup" coach who works with startups around the world and volunteers for the non-profit Lean Startup Circle.

 Joining us today in studio, C. R. Kannan, M. D.                   Dr. Kannan is presently Director of Endocrinology and Metabolism at Red Rock Medical Center in Las Vegas.  He served as Professor of Internal Medicine at the University of Nevada School of Medicine in Las Vegas from 2009 to 2013, with teaching and patient responsibilities. He was also Consultant in Endocrinology at Southwest Medical Associates in Las Vegas, from 2003 to 2010.  He moved to Nevada in 2003, following many years of academic and clinical practice in Chicago.      He is the former Chairman of Endocrinology at Cook County Hospital in Chicago, and Associate Chairman of Endocrinology at Rush Presbyterian St. Luke’s Medical Center.  He was responsible for the combined Endocrinology Fellowship Program of Rush Presbyterian and Cook County Hospitals.  He is a tenured Professor of Medicine at Rush University, Chicago.   During his tenure at Cook County and Rush Presbyterian, he won the Teacher of the Year Award ten (10) times.   He has single-authored four (4) medical textbooks, and has served as an editor of the Year Book of Endocrinology for 15 years.  He has also co-authored several original articles in peer-reviewed journals.

Mary and a fellow 4th-year student, Charlotte Rolle, interviewed Dr. Jordan Cohen, President Emeritus of the Association of American Colleges (AAMC), Professor of Medicine and Health Policy at George Washington University, and former Professor and Associate Chairman of Medicine at the University of Chicago, during his recent visit to the University of Chicago Pritzker School of Medicine as keynote speaker and visiting professor for the Alpha Omega Alpha honor society induction banquet. They discussed various aspects of medical education and recent developments in its evolution. If you have questions for us, please send them to pritzkerquestions@gmail.com. Or, call (773) 336-2POD and leave us a message. Click here to get the full transcript for this episode.

"Virtually every virus and worm that circulates the Internet today is ""protected"" by some form of obfuscation that hides the code's true intent. In the Window's world where worms prevail, the use of tools such as UPX, ASPack, and teLock has become standard. Protection of malicious code is not the only goal of binary obfuscators however which can be used to protect intellectual property. In the Linux world, tools such as Burneye and Shiva exist which can be used in ways similar to any Window's obfuscation tool. To fight such methods, analysts have created specific tools or techniques for unraveling these code obfuscators in order to reveal the software within. To date, in the fight against malware, anti-virus vendors have had the luxury of focusing on signature development since obfuscation of malware has presented little challenge. To combat this, malware authors are rapidly morphing their code in order to evade quickly developed and deployed signature-matching routines. What will happen when malware authors begin to morph their obfuscation techniques as rapidly as they morph their worms? While not designed specifically as a malware protection tool, one program, Shiva, aims to do exactly that. Shiva forces analysis of malicious code to be delayed while analysts fight through each novel mutation of Shiva's obfuscation mechanism. This, in effect, provides the malware a longer period of time to wreak havoc before countermeasures can be developed. This talk will focus on the use of emulated execution within IDA Pro to provide a generic means for rapidly deobfuscating protected code. Capabilities of the emulation engine will be discussed and the removal of several types of obfuscation will be demonstrated. Finally, the development of standalone deobfuscation tools based on the emulation engine will be discussed. Chris Eagle is the Associate Chairman of the Computer Science Department at the Naval Postgraduate School (NPS) in Monterey, CA. A computer engineer/scientist for 18 years, his research interests include computer network operations, computer forensics and reverse/anti-reverse engineering."

"Virtually every virus and worm that circulates the Internet today is ""protected"" by some form of obfuscation that hides the code's true intent. In the Window's world where worms prevail, the use of tools such as UPX, ASPack, and teLock has become standard. Protection of malicious code is not the only goal of binary obfuscators however which can be used to protect intellectual property. In the Linux world, tools such as Burneye and Shiva exist which can be used in ways similar to any Window's obfuscation tool. To fight such methods, analysts have created specific tools or techniques for unraveling these code obfuscators in order to reveal the software within. To date, in the fight against malware, anti-virus vendors have had the luxury of focusing on signature development since obfuscation of malware has presented little challenge. To combat this, malware authors are rapidly morphing their code in order to evade quickly developed and deployed signature-matching routines. What will happen when malware authors begin to morph their obfuscation techniques as rapidly as they morph their worms? While not designed specifically as a malware protection tool, one program, Shiva, aims to do exactly that. Shiva forces analysis of malicious code to be delayed while analysts fight through each novel mutation of Shiva's obfuscation mechanism. This, in effect, provides the malware a longer period of time to wreak havoc before countermeasures can be developed. This talk will focus on the use of emulated execution within IDA Pro to provide a generic means for rapidly deobfuscating protected code. Capabilities of the emulation engine will be discussed and the removal of several types of obfuscation will be demonstrated. Finally, the development of standalone deobfuscation tools based on the emulation engine will be discussed. Chris Eagle is the Associate Chairman of the Computer Science Department at the Naval Postgraduate School (NPS) in Monterey, CA. A computer engineer/scientist for 18 years, his research interests include computer network operations, computer forensics and reverse/anti-reverse engineering."